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The duration of hemodialysis (HD) in methanol poisoning
(MP) is dependent on the methanol concentration, the
operational parameters used during HD, and the presence
and severity of metabolic acidosis. However, methanol assays
are not easily available, potentially leading to undue
extension or premature termination of treatment. Here we
provide a prediction model for the duration of high-efficiency
HD in MP. In a retrospective cohort study, we identified 71
episodes of MP in 55 individuals who were treated with
alcohol dehydrogenase inhibition and HD. Four patients had
residual visual abnormality at discharge and only one patient
died. In 46 unique episodes of MP with high-efficiency HD the
mean methanol elimination half-life (T1/2) during HD was
108min in women, significantly different from the 129min in
men. In a training set of 28 patients with MP, using the 90th
percentile of gender-specific elimination T1/2 (147min in men
and 141min in women) and a target methanol concentration
of 4mmol/l allowed all cases to reach a safe methanol of
under 6mmol/l. The prediction model was confirmed in a
validation set of 18 patients with MP. High-efficiency HD time
in hours can be estimated using 3.390× (Ln (MCi/4)) for
women and 3.534× (Ln (MCi/4)) for men, where MCi is the
initial methanol concentration in mmol/l, provided that
metabolic acidosis is corrected.
Kidney International (2015) 88, 1170–1177; doi:10.1038/ki.2015.232;
published online 5 August 2015
KEYWORDS: hemodialysis; kinetic modeling; methanol poisoning
Methanol poisoning (MP), if untreated, may result in
blindness, coma, and death, and today it still remains a
xenobiotic of concern in outbreaks.1–5 Hemodialysis (HD)
can efficiently remove methanol and its toxic metabolite
formic acid while correcting metabolic acidosis and improv-
ing patient outcome.4–7 Current guidelines suggest instituting
HD when the methanol concentration is 415.6 mmol/l
(50 mg/dl) until concentrations are inferior to 6.25 mmol/l
(20 mg/dl) and acid–base disturbance has been corrected.8,9
However, methanol concentrations may not be readily
available in an appropriate time frame, which may lead to
either undue prolongation or premature termination of HD.
Accordingly, Hirsch et al.10 proposed a formula to predict
dialysis duration in toxic alcohol poisoning. Their proposal
is based on a natural logarithmic formula requiring the
knowledge of total body water using Watson’s formula (based
on age, gender, height, and weight),11 and the knowledge of
dialyzer’s urea clearance at the prescribed blood flow and
dialysate flow. The formula has been generated using two
cases of MP and subsequently validated in three other cases.12
However, in the era of high-efficiency dialysis, we hypothe-
sized that estimation of dialysis duration based on the
methanol’s elimination half-life (T1/2) would be simpler and
more intuitive in predicting HD duration.
The aims of the present study were (1) to describe the
clinical presentation, outcomes, and methanol toxicokinetics
in a large cohort of methanol poisoned patients, (2) to use a
training set of cases of MP to determine methanol elimination
T1/2 during HD and to propose a simplified model to predict
HD time, and (3) to validate the proposed model using a
validation cohort.
RESULTS
Characteristics at presentation and clinical outcomes
The study flow chart is shown in Figure 1. Between December
1997 and June 2013, among the 73 eligible MP episodes, 71
episodes occurred in 55 patients who required HD (Table 1).
Baseline characteristics of subjects are presented in
Table 1. Most patients were middle-aged healthy men with
a history of psychiatric disorder. MP was intentional in 66
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episodes (93%). Characteristics of poisoning episodes are
summarized in Table 1. Nearly half of the cohort also co-
ingested other substances.
In most episodes, there were a mild metabolic acidosis,
a slightly elevated anion gap, and an increased osmol gap.
When compared with other patients, those who presented
with a decreased level of consciousness were significantly
more acidotic and had a higher osmol gap (Table 2). Among
the nine patients who had visual abnormalities at presenta-
tion, four had residual visual symptoms at discharge.
Compared with patients without any visual symptoms, those
with persistent visual abnormalities had a significantly lower
median initial pH (7.14 vs. 7.29 P= 0.01), without a
significantly higher anion gap (27 vs. 19 mmol/l, P= 0.08)
or an osmol gap (95 vs. 74 mOsm/kg, P= 0.54). Only one
patient with extreme acidosis (pH= 6.85), high anion gap
(40 mmol/l), high osmol gap (184 mOsm/kg), and a methanol
concentration of 115 mmol/l was comatose on admission and
developed cerebral edema resulting in neurologic death. Six
patients experienced complications not directly related to MP
such as pneumonia (n= 4), pyelonephritis (n= 1), and
myocardial infarction (n= 1). MP resulted in a median
hospital stay of 2 days (1, 3) in our center before discharge or
transfer to the referring center.
Determinants of methanol elimination T1/2 during HD
Figure 2 shows methanol elimination T1/2 during HD
according to gender. In univariate linear regression analysis,
T1/2 was positively influenced by the male gender (β= 21 min,
95% confidence interval (CI): 9–34 min, R2= 0.21, P= 0.001)
and increasing weight (β= 0.55, R2= 0.13, P= 0.015). In a
stepwise multiple regression, gender remained the only
significant determinant of methanol elimination T1/2 during
HD. Neither the type of alcohol dehydrogenase (ADH)
inhibition (ethanol or fomepizole), the initial methanol
concentration, nor the HD-related parameters were found
to be significantly associated with the changes in methanol
elimination T1/2 in this cohort.
Eligible cases of methanol poisoning
(n = 73)
Training set of methanol
poisoning (n = 28)
Validation set of methanol
poisoning (n = 18)
No need for HD (n = 2)
Descriptive analysis of methanol poisoning
episodes (n = 71)
Excluded from kinetic
analysis (n = 25):
Qb< 350 ml/min (n = 4)
Insufficient methanol
sampling during HD
(n = 11)
Repeated episode in the
same patient (n = 10)
Figure 1 | Study flow chart. The chart shows the number of eligible
cases of methanol poisoning, the number of cases available for
descriptive analysis, kinetic analysis, and model prediction in training
set and validation set.
Table 1 |Clinical characteristics of patients and episodes of
methanol poisoning
Parameters Value
Subjects characteristics (n) 55
Male gender (n, %) 38 (69)
Age (years) 46 (36,55)
Psychiatric disease (n, %) 48 (87)
Intoxication episode (n) 71
Creatinine on admission (μmol/l) 75 (68,88)
Intentional ingestion (n, %) 66 (90)
Delay between ingestion and ER consultation (min) 230 (90,510)
Delay 24–36 h 4
Delay 36–96 h 2
Delay 496 h 1
Delay between ER and HD (min) 540 (390,705)
Co-ingestion (n, %) 31 (44)
Ethanol 16
Isopropyl 3
Salicylate 2
Acetaminophen 2
Cocaine 2
Cannabis 2
Others 7
⩾ 2 co-ingestants 8
Clinical severity
Glasgow o8 (n, %) 22 (31)
Intubation (n, %) 21 (30)
Requirement for inotropes/vasopressors (n, %) 9 (13)
Visual abnormality at presentation (n, %) 9 (13)
Laboratory
Arterial pH 7.31 (7.23, 7.38)
Anion gap (mmol/l) 16 (13,25)
Osmol gap (mOsm/kg) 74 (37,134)
Initial methanol concentrationa (mmol/l) 61.5 (25.1, 110.7)
Peak methanol concentrationa (mmol/l) 64 (26, 111.4)
Alcohol dehydrogenase inhibition
Ethanol (n, %) 53 (74)
Fomepizole (n, %) 9 (13)
Both (n, %) 9 (13)
Abbreviations: ER, emergency room; HD, hemodialysis.
Values are medians (25th, 75th percentiles).
aTo convert to mg/dl multiply by 3.2.
Table 2 |Determinants of decreased level of consciousness
Level of consciousness
Parameters
Glasgow ⩾8
(n=50)
Glasgow o8
(n=21) P-value
Arterial pH 7.32 (7.26, 7.38) 7.26 (7.13, 7.33) 0.002
Anion gap (mmol/l) 17 (13, 24) 16 (13, 27) 0.30
Osmol gap (mOsm/kg) 52 (33, 108) 131 (79, 164) o0.001
Time to presentation
(min)
233 (91, 642) 253 (105, 510) 0.72
Values are medians (25th, 75th percentiles).
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Training set
The characteristics of training set, which consisted of 28
episodes of MP in 28 subjects (nine women), are shown in
Table 3. Various half-lives were used to model HD duration
to a calculated safe level of methanol o6 mmol/l: the use of
gender-specific 90th percentiles and targeting a methanol
level of 4 mmol/l by the end of HD session proved to be the
most robust method in achieving a safe methanol level for all
individuals using the bootstrap method (Table 4). Table 5
shows the delivered HD time, the individual modeling of HD
time to a methanol of 6 mmol/l, and the 90th percentile
modeling of HD time to 4 mmol/l (Figure 3). In the training
set, the delivered HD time was longer compared with the
individual modeling HD time by 172 min (95% CI: 107–237)
but not statistically longer compared with the 90th percentile
model of HD time by 7 min (95% CI: − 52–66).
Validation of the proposed model for prediction of HD
duration
The validation set consisted of 18 episodes of MP in 18
patients (seven women), which were independent from the
training set. The validation set was comparable to the training
set in terms of comorbidities, clinical severity of intoxication,
biochemical abnormalities, ADH inhibition, and methanol
elimination T1/2 during HD (Table 3). The 90th percentile
modeling of HD time using a target methanol concentration
of 4 mmol/l allowed to reach a calculated safe methanol
concentration of o6 mmol/l in all cases (Figure 3). Table 5
shows the delivered HD time, the individual modeling of HD
time to methanol concentration of o6 mmol/l, and the 90th
percentile modeling of HD time. The delivered HD time was
longer compared with the individual modeling HD time by
192 min (95% CI: 128–255) and longer compared with the
90th percentile model of HD time by 56 min (95% CI:
5–108). Finally, Figure 4 shows that, based on the 90th
percentile modeling to a methanol of 4 mmol/l, all patients in
both training and validation set of MP would have received
the minimum HD duration based on the individual modeling
to a methanol concentration of 6 mmol/l.
Figure 5 illustrates a gender-specific nomogram to predict
HD time, using high-efficiency HD, based on the 90th
percentile of elimination T1/2 and targeting a methanol
concentration of 4 mmol/l. To predict dialysis time (hours)
based on initial methanol concentration, we propose using
the following formulas: 3.390 × (Ln(MCi/4)) for women and
3.534 × (Ln(MCi/4)) for men, where MCi is the initial
methanol concentration (mmol/l).
As part of the sensitivity analysis, we conducted a leave-
one-out cross-validation, which confirms that the 90th
Methanol elimination T1/2 according to gender
P = 0.001
140
120
100
80
60
40
20
0
Men (n = 30) Women (n = 16)
M
et
ha
no
l h
al
f-l
ife
 (m
in)
Figure 2 |Gender-specific methanol elimination half-life. The
figure shows the methanol elimination T1/2 by high-efficiency
hemodialysis with a blood flow of 4350 ml/min and a large surface
area of dialysis filter of 42.0 m2. Bars represent 95% confidence
intervals.
Table 3 |Clinical characteristics and episode of methanol
poisoning in training and validation set
Parameters
Training set
(n=28)
Validation set
(n=18)
Age (years) 47 (40, 52) 49 (41, 56)
Creatinine on admission
(μmol/l)
77 (72, 87) 71 (64, 87)
Psychiatric disease 24 (86) 15 (83)
Male gender (n, %) 19 (68) 11 (61)
Weight (kg) 69 (67, 80) 70 (67, 80)
Multiple substances 15 (54) 9 (50)
Intentional ingestion 26 (93) 17 (94)
Delay between ER and HD
(min)
528 (330, 720) 540 (420, 622)
Clinical severity
Glasgow o8 (n, %) 12 (43) 5 (28)
Intubation (n, %) 11 (39) 5 (28)
Requirement for
inotropes/vasopressor (n, %)
5 (18) 1 (6)
Visual abnormality at
presentation (n, %)
3 (18) 2 (11)
Laboratory
Arterial pH 7.30 (7.23, 7.36) 7.30 (7.21, 7.39)
Anion gap (mmol/l) 17 (13, 26) 16 (13, 24)
Osmol gap 126 (57, 163) 68 (38, 108)
Initial methanol concentrationa
(mmol/l)
97 (36, 124) 44 (21, 74)
Peak methanol concentrationa
(mmol/l)
97 (47, 139) 44 (26, 74)
Final methanol concentrationa
(mmol/l)
3.4 (2.6–4.2) 3.5 (2.4, 4.2)
Alcohol dehydrogenase inhibition
Ethanol (n, %) 23 (82) 11 (61)
Fomepizole (n, %) 2 (7) 4 (22)
Both (n, %) 3 (11) 3 (17)
T1/2 overall (min) 126 (108, 138) 133 (119, 139)
Range (min) 77–155 60–147
T1/2 in women (min) 100 (98, 121) 119 (75, 135)
90th percentile (95% CI by
bootstrap)
141 (121–141) 142 (123–142)
T1/2 in men (min) 132 (115, 141) 137 (129, 139)
90th percentile (95% CI by
bootstrap)
147 (138–155) 145 (138–147)
Abbreviations: CI, confidence interval; ER, emergency room; HD, hemodialysis.
Values are median (25th, 75th percentile) or mean (95% confidence interval).
aTo convert to mg/dl multiply by 3.2.
1172 Kidney International (2015) 88, 1170–1177
c l in i ca l inves t iga t ion P Lachance et al.: Duration of hemodialysis in methanol poisoning
percentile of T1/2 and a target methanol concentration of
4 mmol/l achieved a methanol concentration of o6 mmol/l
in all cases, while resulting in the lowest HD duration time
(Supplementary Table S4).
DISCUSSION
This study proposes a simple calculation derived from a
kinetic model using the 90th percentile methanol elimination
T1/2 (147 min in men and 141 min in women) and targeting a
methanol concentration of 4 mmol/l to predict the optimal
duration of high-efficiency HD. This approach proved to be
valid in our study cohort and achieved a safe methanol
concentration in all cases. This study also suggests that our
formula may obviate the need for costly monitoring of
methanol concentrations during HD.
Methanol is a small molecule (32 Da), with a small volume
of distribution (0.6–0.7 l/kg) and no protein binding. The
elimination of methanol without an antidote is of zero order
Table 4 | Impact of the choice of target methanol concentration on the calculated residual methanol concentration using 90th
percentile of methanol elimination half-life
Parameters Training set (n=28) Validation set (n=18)
Target (methanol) of 6mmol/l
Calculated residual (methanol) (mmol/l) 4.6 (2.4, 5.3) 5.0 (4.3, 5.5)
Calculated residual (methanol) 46mmol/l (n, %) 1 (4) 2 (11)
95% CI by bootstrap (n)a 0–3 0–7
Target (methanol) of 5mmol/l
Calculated residual (methanol) (mmol/l) 3.8 (1.9, 4.3) 4.0 (3.5, 4.5)
Calculated residual (methanol) 46mmol/l (n, %) 1 (4) 0 (0)
95% CI by bootstrap (n)a 0–1 0–3
Target (methanol) of 4mmol/l
Calculated residual (methanol) (mmol/l) 3.0 (1.4,3.4) 3.1 (2.7, 3.6)
Calculated residual (methanol) 46mmol/l (n, %) 0 (0) 0 (0)
95% CI by bootstrap (n)a 0–0 0–0
Abbreviation: CI, confidence interval.
Values are median (25th, 75th percentile).
a95% CI of the number of subjects with calculated residual methanol concentration (methanol) 4to 6mmol/l using the bootstrap method.
Table 5 |Delivered, individual modeling and 90th percentile modeling of HD time
Parameters Training set (n=28) Validation set (n=18)
Delivered HD time (min) 612 (519–704) 509 (417–601)
95% CI by bootstrap (min) 527–693 431–588
Individual modeling HD timea (min) 440 (369–510) 318 (237–398)
95% CI by bootstrap (min) 376–506 245–388
Delivered HD time—individual modeling HD time (min) 172 (107–237) 192 (128–255)
95% CI by bootstrap (min) 122–225 142–251
90th percentile modeling HD timeb (min) 605 (536–674) 453 (369–537)
95% CI by bootstrap (min) 522–680 370–531
Delivered HD time—90th percentile modeling HD time (min) 7 (−52–66) 56 (5–108)
95% CI by bootstrap (min) −42–67 11–109
Abbreviations: CI, confidence interval; HD, hemodialysis. Values are mean (95% CI).
aIndividual modeling of HD time is defined as time to a calculated residual methanol concentration of 6mmol/l using each case’s baseline methanol concentration and
elimination half-life.
b90th percentile modeling of HD time is defined as the time to achieve a methanol concentration of 4mmol/l using each case’s baseline methanol concentration and the
90th percentile of gender-specific methanol elimination half-life of the training set.
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Figure 3 |Calculated methanol concentration by the end of the 90th
percentile modeling of HD to a target methanol of 4mmol/l. Using
the 90th percentile of the gender-specific elimination T½ of methanol
during HD and targeting a methanol concentration of 4mmol/l (target
concentration), all cases of methanol poisoning were well below
6mmol/l (safe concentration) during high-efficiency HD both in the
training set and in the validation set of methanol poisoning episodes.
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with an elimination rate of 85 mg/l/h at low concentration.13
When fomepizole or ethanol is used, the apparent T1/2
is significantly prolonged to ~ 54 and 43 h, respectively, with
the total body elimination coming mostly from the lungs and
the kidneys (o10 ml/min).14,15 The systematic review and the
clinical guidelines published by the EXTRIP workgroup
reported 114 patients, where the mean T1/2 during HD was
3.4 h (range: 0.6–13.1).9 Recently, in 11 patients, Zacharof
et al.16 showed that the mean methanol elimination
T1/2 during HD was 3.7± 1.4 h. This is ~ 100 min longer
compared with the elimination T1/2 reported in the present
study. This difference is likely the result of lower blood flow,
(180–250 ml/min vs. 4350 ml/min), lower membrane sur-
face area (1.5–1.6 m2 vs. 42.0 m2), and lower dialysate flow
(500 ml/min vs. 750 ml/min) in their study. Whereas Hirsch’s
approach is mechanistically sophisticated, it is slightly complex
and has only been validated in three cases of MP.10,12
Unfortunately, we could not validate Hirsch’s approach
in our cohort as the information on height was unavailable
in clinical records, and therefore we could not estimate total
body water using Watson’s equation.
To our knowledge, this is the first study to show that men
had a longer methanol elimination T1/2 than women. This
difference is likely the result of a lower methanol volume of
distribution in women. It is unlikely that the sex differences
in clearance are explained by differences in endogenous
elimination during ADH inhibition, given its negligible
contribution to total methanol clearance during HD.
In the present study, we did not observe any significant
associations between HD parameters and the methanol
elimination T1/2. This is in contrast to what was previously
reported and theoretically expected.16,17 This is potentially
explained by a lack of variability in the delivered blood flow in
all subjects (4350 ml/min), a standard and a constant
dialysate flow of 750 ml/min, and minute differences in the
surface area of dialysis membrane (all above 2.0 m2). Had
these differences in HD parameters been greater within our
cohort, it would have been possible to see the relationship
between HD parameters and T1/2.
17 In the 71 episodes of MPs
in our study, only 4 episodes (6%) were excluded because
of low and variable blood flow during HD. Therefore,
high-efficiency HD was possible for 94% of the episodes,
supporting that our findings can have an impact on the
management of the majority of MP, when HD is indicated.5,9
In Canada, most cases of MP result from an acute
intentional ingestion. The demographic characteristics, prog-
nostic factors, and outcomes of patients treated for MP in large
outbreaks are mainly derived from unintentional exposure. In
these conditions, the mortality rate has been reported to be as
high as 34%.18–21 However, there is little data available on the
clinical characteristics and the outcome of patients with MP in
the context of intentional MP. Generally, our cases consulted
earlier and they were less acidotic at presentation as compared
with what is generally reported in series of unintentional
MP.18–25 In our cohort, only one patient died and four patients
had persistent visual abnormalities. The better prognosis of
our cohort could also be explained by an unhindered access to
ADH inhibitors and easier access to HD centers, which may be
overwhelmed in epidemics.18–25
In the event of a late presentation, most of the methanol
may have already been metabolized to formic acid and the
interpretation of the osmolal gap and methanol concentration
alone may therefore underestimate the severity of the intoxica-
tion. In our study, there was no measurement of formic acid.
Formic acid is a small molecule (46 Da) with small volume of
distribution (0.5 l/kg) and no protein binding. Contrary to
methanol, which has a long elimination T1/2 under ADH
inhibition, formic acid has a much shorter elimination T1/2.
Hantson et al.26 examined the elimination T1/2 of formic acid
before, during, and after HD and showed elimination T1/2 of
6.0± 3.3, 1.8± 0.8, and 3.9± 2.0 h, respectively. They also
reported that formate clearance by HD was 176± 43ml/min.
However, none of the HD parameters of these subjects were
reported.26 In the study presented by Zakharov et al.,16 where a
detailed description of HD parameters was available, the T1/2 of
formate was 1.6± 0.4 h, nearly half of the reported methanol
elimination T1/2 (3.7± 1.4 h).16
Strengths and limitations
To our knowledge, this is the largest reported cohort of
intentional MP, with detailed clinical characterization and
kinetic analysis. This study’s proposed approach to predict
HD duration has several strengths and advantages. First, it
relies on the determination of methanol elimination T1/2,
which is intuitive to clinicians. Second, the prediction model
has been created using a relatively large training and
validation sets of data. Its reliability has been tested using
bootstrap and leave-one-out cross-validation, further
strengthening the consistency and safety of the model. Third,
because of delays in obtaining methanol concentrations
during HD, our data suggest that the delivered HD time is
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Figure 4 | Individual vs. 90th percentile modeling of HD time. The
figure shows the calculated HD time to a methanol concentration of
6 mmol/l based on each patient’s methanol elimination half-life and
initial methanol concentration on the vertical axis. The horizontal axis
shows the 90th percentile modeling of HD time to a methanol
concentration of 4 mmol/l. This figure shows that the model ensures
that all patients receive at least the required HD duration as defined
by the individual modeling of HD time to a calculated methanol
concentration of 6mmol/l.
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~ 3 h longer than what is required to reach a safe level of
6 mmol/l. Even in our center where methanol concentrations
are relatively easy to obtain, the proposed approach, even
though conservative, still allowed to reduce the HD duration
as compared with the conventional method of methanol
monitoring in our validation set. The study therefore provides
valuable information for safe management of patients and
responsible allocation of scarce resources. Finally, our
prediction model may be particularly useful when methanol
monitoring cannot be performed in a timely manner.
The study also has the inherent limitations of a retro-
spective study. Although data were available for the majority
of the patients, the long-term outcome of patients could not
be assessed. The proposed model is only applicable for HD
(not continuous forms of renal replacement therapy) when a
constant blood flow of 4350 ml/min and high-efficiency
large (42 m2) dialyzers are used. As we selected the 90th
percentile of methanol elimination T1/2, there was a small
likelihood of under-dialysis, but this was compensated by
targeting a lower methanol concentration of 4 mmol/l in our
model. It should be noted that, in this cohort, early
consultation after consumption of methanol resulted in a
small percentage of overtly acidotic patients. As formic acid
measurements are not accessible in most hospitals, it is also
recommended to monitor the acid–base status during HD.
Finally, as all patients were adults, our findings cannot be
generalized to the pediatric population.
CONCLUSION
In the context of high-efficiency HD, our proposed prediction
model, which is based on the 90th percentile of the methanol
elimination T1/2 and a target methanol concentration of
128
120
112
104
96
88
80
72
0
8
16
24
32
40
48
56
64
128
120
112
104
96
88
80
72
0
8
16
24
32
40
48
56
64
Men
Women
0 1 2 3 4 5 6 7 8 9 10 11
0 1 2 3 4 5 6 7 8 9 10 11 12
90th percentile modeling of HD time (hours)
90th percentile modeling of HD time (hours)
400
375
350
325
300
275
250
225
200
175
150
125
100
75
50
25
0
400
375
350
325
300
275
250
225
200
175
150
125
100
75
50
25
0
M
et
ha
no
l c
on
ce
nt
ra
tio
n 
(m
g/d
l)
M
et
ha
no
l c
on
ce
nt
ra
tio
n 
(m
g/d
l)
M
et
ha
no
l c
on
ce
nt
ra
tio
n 
(m
mo
l/l)
M
et
ha
no
l c
on
ce
nt
ra
tio
n 
(m
mo
l/l)
a
b
Figure 5 |Gender-specific nomogram for prediction of high-efficiency HD time. The figure shows the gender-specific (women (a), men (b))
nomogram for prediction of high-efficiency HD time using dialysis blood flow of 4350 ml/min, membrane surface area of 42.0 m2, and a
dialysate flow of 750 ml/min. To ensure that all subjects are adequately treated to a methanol concentration of at least 6 mmol/l, the target
methanol concentration using the nomogram should be 4mmol/l. HD time in hours can be estimated using the 3.390 × (Ln(MCi/4)) for women
and 3.534 × (Ln (MCi/4)) for men, where MCi is the initial methanol concentration (mmol/l) and 4 is the target methanol concentration in mmol/l.
To convert the methanol concentration from mmol/l to mg/dl, multiply by 3.2.
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4 mmol/l, resulted in a safe methanol concentration of below
6mmol/l in all subjects.
MATERIALS AND METHODS
Study design
This is a retrospective single-center study conducted at CHU de
Québec-Hôtel Dieu de Québec Hospital (Quebec City, Canada). All
adult cases of MP who were referred for HD from December 1997 to
June 2013, and had baseline methanol levels of 410 mmol/l, were
eligible. To determine the outcome of our cohort, all eligible cases of
MP treated by HD were included in the analysis. Demographic
characteristics and medical history were extracted from medical files.
Initial biochemical and acid–base status as well as initial clinical
status and evolution were also recorded. Clinical parameters of
interest at initial presentation were (a) decreased level of conscious-
ness defined as a Glasgow score o8, (b) severe hypotension defined
as the need for inotropic/vasopressor support, (c) need for
intubation, and (d) patient-reported visual abnormality. Clinical
outcomes following dialysis such as death, infection, reported sight
loss by the patient, the presence of neurological deficit, and the
duration of intensive care unit stay were recorded.
Treatment protocol
Indications for HD were as follows: significant metabolic acidosis (pH
o7.25–7.30), visual abnormalities, deteriorating vital signs despite
intensive supportive care, electrolyte imbalance unresponsive to
conventional therapy, or a serum methanol concentration 415.6
mmol/l (50mg/dl) as recommended.8,9 Prescribed dialysis parameters
were blood flow of 350–400ml/min, dialysate flow of 750ml/min, the
use of high-efficiency filters with mass transfer-area coefficient (KoA)
4600, and membrane surface areas of 2.0–2.2m2 using the following
filters: Polyflux 21 l (n= 25), DICEA210 (n= 20), Optiflux F20
(n= 14), Nephral 500 (n= 5), Exeltra 210 (n= 3), Xenium H21
(n= 2), and Evodial 2.2 (n= 2). Treatment was performed using a
dual lumen catheter inserted in the internal jugular or femoral veins.
Ethanol- (~20mmol/l) and phosphate-enriched (1mmol/l) dialysate
with a bicarbonate concentration of 30–38mmol/l was used for all
patients (except when fomepizole was used during HD). All patients
received heparin 1000–1500 IU as bolus and 500–1000 IU/h during
HD session. During HD, the interval of serial measurements of
methanol concentrations was prescribed according to the treating
physician. HD was discontinued when a safe concentration of
methanol (o6mmol/l) was achieved and acid–base balance was
restored. Methanol concentration was determined using a kinetic
enzymatic method based on Alcohol Oxidase.
Alcohol dehydrogenase inhibition was performed with either
ethanol, fomepizole, or a combination of both. The initial dose and
perfusion rate of ethanol were administered according to the
recommended protocol.8 Target serum ethanol levels ranged from
20 to 30mmol/l, and the perfusion was adjusted to maintain this
target before and throughout the dialysis session. When fomepizole
was used before HD, it was given at a dose of 15mg/kg with repeated
administration of 10mg/kg every 12 h up to the initiation of dialysis
and then after every 4 hours during HD, as recommended.8 In case of
fomepizole treatment, an ethanol-free dialysate was used during HD.
Every patient was also treated with folinic acid (50mg every 6 h).
Kinetic modeling and methanol elimination T1/2
To ensure a reliable determination of T1/2, we excluded MP episodes
where less than three measurements of methanol concentration were
performed during HD (n= 11). Further, to ensure that only high-
efficiency HD was studied, we excluded cases with suboptimal blood
flow (o350 ml/min, n= 4). All HD sessions were performed with
high-efficiency filters with a surface area 42.0 m2 and a dialysate
flow of 750 ml/min. A total of 56 episodes of MP were available for
kinetic modeling, but 10 were excluded for repeated episodes of MP
(Figure 1). Methanol elimination T1/2 for each individual episodes of
MP was calculated using serum methanol concentrations during HD
and plotted through a one-phase decay exponential regression
analysis. The median R2 for each T1/2 determination was 0.99
(ranging from 0.94 to 1.00), therefore establishing the robustness of
the kinetic modeling for each episode of MP.
Modeling of HD duration in a training set
To avoid selection bias and ensure the independence of observation,
the first MP episode, stratified for gender and excluding repeated
MP of 28 patients (19 male), was used to construct a new model to
predict the optimal HD duration to achieve a calculated safe
methanol concentration of o6 mmol/l.
Individual modeling of HD time to a safe methanol concentration
of 6 mmol/l was obtained using each individual’s elimination T1/2 by
the following formula:
Individual Modeling of HD Time ¼ Ln MCi=6ð Þ=k;
where k is the corresponding constant rate to the individual’s
T1/2 (i.e., Ln(2)/T1/2), MCi is the initial methanol concentration
(mmol/l), and 6 is the safe level of methanol in mmol/l.
Specified percentile modeling of HD time was performed using
median, 75th and 90th percentiles of gender-specific T1/2 and by
sequentially targeting a final methanol concentration of 6, 5, 4, 3,
and 2 mmol/l, using the following formula:
Specif ied Percentile Modeling of HD Time
¼ Ln MCi=MCtð Þ=kpercentile;
where kpercentile is the corresponding constant rate to the specified
percentile T1/2 (i.e., Ln(2)/T1/2 percentile), MCi is the initial
methanol concentration (mmol/l), and MCt is the target methanol
concentration (mmol/l). The Supplementary Tables S1–S3 allow to
see that the 90th percentile T1/2 and a target methanol concentration
of 4 mmol/l predicted a safe methanol level of o6 mmol/l for all
patients (number of patients with methanol 46 mmol/l is 0 (95%
CI:0–0) using the bootstrapping method).
On the basis of these results, we proposed the gender-specific
90th percentile modeling HD time to achieve a target methanol of
4 mmol/l by the following formula:
90th Percentile Modeling of HD Time
¼ Ln MCi=4ð Þð Þ=kgender-specif ic 90th percentile;
where MCi is the initial methanol concentration and k gender-specific
90th percentile corresponds to the Ln(2)/gender-specific 90th percentile
T1/2 of 141 and 147min, respectively, for women and men.
Validation set
To validate our prediction model in an independent set of subjects,
we examined the impact of the 90th percentile modeling of HD time
on its capacity to achieve a safe level of methanol concentration in
the remaining cases of MP.
Statistical analysis
Data are presented as median (25th, 75th percentile) or mean (95%
CIs) for continuous variable and number (percentage) for categorical
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variable. Student’s t-test was used to compare quantitative variables
between the two groups. As a subject could have had more than one
episode of MP requiring HD, we only included the data of the first
intoxication episode for each subject (n= 46) for the following
analyses. A one-phase decay robust exponential regression analysis
with a robust fitting method and a plateau constrain to a value of40
was used to determine T1/2 for each patient (Prism 6.0). To study the
determinants of methanol T1/2 during HD, we used a multiple linear
regression analysis. We used age, gender, weight, initial methanol
concentration, delivered dialysis blood flow, type of filter, and type of
ADH inhibition as potential explanatory variables for the variability that
was detected in the methanol elimination T1/2. A thousand bootstrap
samples, stratified by gender, were generated from the training and
validation data sets. Gender-specific T1/2 50th, 75th, and 90th
percentiles, the mean of individual modeling of HD time, specified
percentile modeling of HD time sequentially targeting the final
methanol level of 6, 5, 4, 3, 2mmol/l, residual methanol concentration,
and the proportion of patients with residual methanol concentration
46mmol/l were calculated in each of the bootstrap sample. The 95%
bootstrap confidence intervals were obtained using the 2.5th and 97.5th
percentiles of each variable. As part of the sensitivity analysis, we
performed leave-one-out cross-validation. Statistical analyses were
performed with SAS, version 9.3 (SAS Institute, Cary, NC, USA). A
P-value o0.05 was considered significant.
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